DR ANNA Lavelle has announced her departure as Chair of Medicines Australia, ending a tenure marked by significant governance and strategic advances.
Dr Lavelle, who joined as an independent Director in 2017 and became Chair in 2018, will complete her term in early 2025.
Reflecting on her role, she said, "Medicines Australia placed great faith in me as independent Chair, and I worked hard to meet those expectations".
"Balancing industry needs with government policy goals has been challenging, but I'm proud of our achievements in strengthening our position with stakeholders," Dr Lavelle said.
Medicines Australia CEO Liz de Somer praised Dr Lavelle's contributions, saying, "Anna has been a fearless leader and a mentor to me".
"Her commitment to improving patient outcomes and advancing the sector is unmatched."
The organisation also welcomed five new Board Directors last week: Tori Brown (Lilly), Kathryn Evans (BioMarin), David Pearce (Takeda), Owen Smith (BMS), and Nirelle Tolstoshev (Astellas).
Adam Roach (Beigene) was also re-elected for a second term.
These additions replace departing members, bringing fresh perspectives and continuity to the Board, stated the group.
Dr Lavelle expressed confidence in the incoming Directors, noting their expertise will be crucial as the Board focuses on modernising Australia's health technology assessment (HTA) system and maintaining the country's global competitiveness in clinical trials.
De Somer affirmed this priority, emphasising the need for collective commitment to HTA reforms and strategic goals.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Nov 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Nov 24
